PRNB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PRNB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Principia Biopharma's Operating Income for the three months ended in Jun. 2020 was $9.88 Mil. Principia Biopharma's Interest Expense for the three months ended in Jun. 2020 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies interest coverage is at least 5. Principia Biopharma Inc has enough cash to cover all of its debt. Its financial situation is stable.
(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Principia Biopharma's Interest Coverage or its related term are showing as below:
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The historical data trend for Principia Biopharma's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Principia Biopharma Annual Data | |||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | |||||
Interest Coverage | - | - | No Debt | No Debt |
Principia Biopharma Quarterly Data | |||||||||||||
Dec16 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | |
Interest Coverage | Get a 7-Day Free Trial | No Debt | No Debt | No Debt | N/A | N/A |
For the Biotechnology subindustry, Principia Biopharma's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Principia Biopharma's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Principia Biopharma's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
If Interest Expense is negative and Operating Income is positive, then
Interest Coverage | = | -1 | * | Operating Income | / | Interest Expense |
Else if Interest Expense is negative and Operating Income is negative, then
The company did not have earnings to cover the interest expense. |
Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then
The company had no debt (1). |
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Principia Biopharma's Interest Coverage for the fiscal year that ended in Dec. 2019 is calculated as
Here, for the fiscal year that ended in Dec. 2019, Principia Biopharma's Interest Expense was $0.00 Mil. Its Operating Income was $-58.77 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Principia Biopharma had no debt (1). |
Principia Biopharma's Interest Coverage for the quarter that ended in Jun. 2020 is calculated as
Here, for the three months ended in Jun. 2020, Principia Biopharma's Interest Expense was $0.00 Mil. Its Operating Income was $9.88 Mil. And its Long-Term Debt & Capital Lease Obligation was $12.80 Mil.
GuruFocus does not calculate Principia Biopharma's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's Financial Strength is.
Principia Biopharma (NAS:PRNB) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Thank you for viewing the detailed overview of Principia Biopharma's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.
Patrick Machado | director | 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107 |
Stefani Wolff | officer: Chief Development Officer | C/O PRINCIPIA BIOPHARMA INC., 400 EAST JAMIE COURT, SUITE 302, SOUTH SAN FRANCISCO CA 94080 |
Daniel J. Becker | director | C/O NEW LEAF VENTURE PARTNERS, TIMES SQ TOWER, 7 TIMES SQ, STE 3502, NEW YORK NY 10036 |
Martin Babler | director, officer: President, CEO | C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Dolca Thomas | officer: Chief Medical Officer | C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Simeon George | director | 161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428 |
Shawn Tomasello | director | C/O PHARMACYCLICS, INC, 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085 |
Alan Colowick | director | C/O THRESHOLD PHARMACEUTICALS, INC., 1300 SEAPORT BOULEVARD, 5TH FLOOR, REDWOOD CITY CA 94063 |
Shao-lee Lin | director | C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301 |
David M Goldstein | officer: Chief Scientific Officer | C/O PRINCIPIA BIOPHARMA INC. 400 EAST JAMIE COURT, SUITE 302 SOUTH SAN FRANCISCO CA 94080 |
Roy C. Hardiman | officer: Chief Business Officer | C/O PHARMACYCLICS, INC. 995 EAST ARQUES AVENUE SUNNYVALE CA 94085 |
Christopher Y Chai | officer: Chief Financial Officer | 2400 BAYSHORE PARKWAY, SUITE 200, MOUNTAIN VIEW CA 94043 |
Biotechnology Value Fund L P | other: See Explanation of Responses | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Bvf Gp Holdings Llc | 10 percent owner | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
Bvf Ii Gp Llc | other: See Explanation of Responses | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
From GuruFocus
By PRNewswire PRNewswire • 09-12-2020
By Business Wire Business Wire • 08-20-2020
By Marketwired Marketwired • 05-12-2020
By PRNewswire PRNewswire • 08-18-2020
By Marketwired Marketwired • 05-26-2020
By Marketwired Marketwired • 01-09-2020
By Marketwired Marketwired • 09-03-2020
By [email protected] insider • 02-17-2020
By Marketwired Marketwired • 06-04-2020
By PRNewswire PRNewswire • 01-27-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.